Abstract
Autologous stem cell transplant (ASCT) is a widely used and safe procedure to treat mostly hematologic diseases. These patients are at risk of infectious complications, which represents a major cause of morbidity and it is the second cause of mortality. This retrospective 12-year analysis of the incidence, type, and severity of infections in 266 consecutive unselected ASCT patients at our institution provides novel information addressing this issue. We included 266 ASCT procedures. Patients included in the 2006–2013 period are referred to as group 1 (ciprofloxacin prophylaxis and ceftazidime-amikacin as empirical antibiotics), and those in the 2013–2017 period are group 2 (levofloxacin prophylaxis and meropenem as empirical antibiotics). The incidence of febrile neutropenia was 72% in group 1 and 86.2% in group 2 (p = 0.004). The majority of infectious episodes were associated with fever of unknown origin: 55% in group 1 and 59% in group 2. Febrile of unknown origin episodes were 82.6% in group 1 and 80% in group 2. Significant differences between both groups were found in age, hypogammaglobulinemia, and advanced disease at ASCT. No differences were found between groups regarding the most common agent documented in positive blood cultures (Gram+ were 66.6% in group 1 and 69% in group 2 (p = 0.68)). Mortality within 100 days of transplant was low, 1.87%. Regardless of the prophylactic regimen used, most patients experience febrile episodes in the ASCT setting, fever of unknown origin is the most common infection complication, and Gram+ agents are prevalent in both groups. Mortality rates were low. According to our results, ASCT is a safe procedure and there is no clear benefit in favor of levofloxacin versus ciprofloxacin prophylaxis. Both anti-infectious approaches are acceptable, yielding similar outcomes.
Similar content being viewed by others
References
Nevill T, Shepherd J, Nantel S (1997) Stem cell transplant-related mortality (TRM) 1985-1996: the Vancouver experience [Abstract 4426]. Blood 90(10):373b
Weaver CH, Schwartzberg LS, Hainsworth J, Greco FA, Li W, Buckner CD, West WH (1997) Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 19:671–678. https://doi.org/10.1038/sj.bmt.1700713
Reich G, Mapara MY, Reichardt P, Do B, Maschmeyer G (2001) Infections complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 27(5):525–529. https://doi.org/10.1038/sj.bmt.1702822
D’Souza A, Fretham C. Summary slides – HCT trends and survival data. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides, 2017. https://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx. Accessed 15 June 2019
Bodey G, Buckley M, Sathe Y, Freireich E (1996) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328–340
Mossad S, Longworth D, Goormastic M, Serkey J, Keys T, Bolwell B (1996) Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 18(2):265–271
Kolbe K, Domkin D, Derigs H, Bhakdi S, Huber C, Aulitzky W (1997) Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 19(2):143–147. https://doi.org/10.1038/sj.bmt.1700621
Barton T, Collis T, Stadtmauer E, Schuster M (2001) Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 32(3):391–395. https://doi.org/10.1086/318491
Auner H, Zebisch A, Ofner P, Sill H, Linkesch W, Krause R (2005) Evaluation of potential risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with lymphoproliferative diseases. Ann Hematol 84(8):532–537
Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, Nadali G, Potenza L, Russo D, Tumbarello M, Nosari A, Aversa F (2017) Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev 31(2):17–29. https://doi.org/10.1016/j.blre.2016.09.002
Looker K, Garnett G, Schmid G (2008). An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. http://www.who.int/bulletin/volumes/86/10/07-046128/en/. Accessed 15 June 2019
Nucci M, Garnica M, Gloria A, Lehugeur D, Dias V, Palma L, Cappellano P, Fertrin KY, Carlesse F, Simões B, Bergamasco MD, Cunha CA, Seber A, Ribeiro MP, Queiroz-Telles F, Lee ML, Chauffaille ML, Silla L, de Souza CA, Colombo AL (2013) Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect 19(8):745–751. https://doi.org/10.1111/1469-0691.12002
Machado C, Martins T, Colturato L, Leite M, Simione A, Souza M (2009) Epidemiology of neglected tropical diseases in transplant recipients. Review of the literature and experience of a Brazilian HSCT center. Rev Inst Med Trop Sao Paulo 51(6):309–324. https://doi.org/10.1590/s0036-46652009000600002
Gale R, Seber A, Bonfim C, Pasquini (2016) Haematopoietic cell transplants in Latin America. Bone Marrow Transplant 51(7):898–905. https://doi.org/10.1038/bmt.2016.35
2017 Social Progress Index. https://www.socialprogressindex.com. Accessed 15 June 2019
Berro M, Arbelbide JA, Rivas MM, Basquiera AL, Ferini G, Vitriu A, Foncuberta C, Fernandez Escobar N, Requejo A, Milovic V, Yantorno S, Szelagoswki M, Martinez Rolon J, Bentolila G, Garcia JJ, Garcia P, Caeiro G, Castro M, Jaimovich G, Palmer S, Trucco JI, Bet LA, Shaw BE, Kusminsky GD (2017) Hematopoietic cell transplantation-specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation. Biol Blood Marrow Transplant 23(10):1646–1650. https://doi.org/10.1016/j.bbmt.2017.06.014
Oliver C, Pierri S, Galeano S, Caneiro A, Bello L, Di Landro J, Miller A, Gai R, Muxí P (2011) Trasplante autólogo de progenitores hematopoyéticos en pacientes con mieloma múltiple: análisis de factores pronósticos y sobrevida. Experiencia del Hospital Británico. Rev Med Urug 27(4):202–210
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431. https://doi.org/10.1093/cid/ciq147
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA 315(8):801–810. https://doi.org/10.1001/jama.2016.0287
Zhang W-X, Zhao Q-Y, Huang H-Q (2015) Febrile neutropenic infection occurred in cancer patients undergoing autologous peripheral blood stem cell transplantation. Transplant Proc 47(2):523–527. https://doi.org/10.1016/j.transproceed.2015.01.013
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biology of blood and marrow transplantation. Am Soc Blood Marrow Transplant 15(10):1143–1238. https://doi.org/10.1016/j.bbmt.2009.06.019
Boeckh M, Gooley TA, Reusser P, Buckner CD, Bowder RA (1995) Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 172(4):939–943. https://doi.org/10.1093/infdis/172.4.939
Gilbert C, Meisenberg B, Vredenburgh J, Ross M, Hussein A, Perfect J, Peters P (1994) Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 12(5):1005–1011. https://doi.org/10.1200/JCO.1994.12.5.1005
National Comprehensive Cancer Network N. Prevention and treatment of cancer-related infections. (Version 1.2019) Available from: https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Accessed 10 March 2019
Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, Kremer L, and Leibovici L (2012). Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. In: Cochrane database of systematic reviews 1:CD004386. https://doi.org/10.1002/14651858.CD004386.pub3
Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Lambertenghi Deliliers G, Lauria F, Foà R, Del Favero A (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353(10):977–987. https://doi.org/10.1056/NEJMoa044097
Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353(10):988–998. https://doi.org/10.1056/NEJMoa050078
Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE, Walsh TJ, Gergis U (2015) Impact of prophylactic levofloxacin on rates of bloodstream infection and fever in neutropenic patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21(10):1808–1814. https://doi.org/10.1016/j.bbmt.2015.06.017
Copeland V, McLaughlin M, Trifilio S (2018) Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation. Clin Transpl 32(1). https://doi.org/10.1111/ctr.13145
Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G, Heinz W, Karthaus M, Kiehl M, Krüger W, Penack O, Reuter S, Ruhnke M, Sandherr M, Salwender HJ, Ullmann AJ, Waldschmidt DT, Wolf HH (2012) Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 91(8):1161–1174. https://doi.org/10.1007/s00277-012-1456-8
Srinivasan A, McLaughlin L, Wang C, Srivastava DK, Shook DR, Leung W, Hayden RT (2014) Early infections after autologous hematopoietic stem cell transplantation in children and adolescents: the St. Jude experience. Transpl Infect Dis 16(1):90–97. https://doi.org/10.1111/tid.12165
Jantunen E, Itala M, Lehtinen T, Kuittinen O, Koivunen E, Leppa S, Juvonen E, Koistinen P, Wiklund T, Nousiainen T, Remes K, Volin L (2006) Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol 76(3):245–250. https://doi.org/10.1111/j.1600-0609.2005.00605.x
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All procedures were in accordance and with the acceptance of the Hospital Britanico’s Ethics Committee and with the Helsinki Declaration of 1975, revised in 2008.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Oliver, A.C., Riva, E., Mosquera, R. et al. Comparison of two different anti-infectious approaches after high-dose chemotherapy and autologous stem cell transplantation for hematologic malignancies in a 12-year period in British Hospital, Uruguay. Ann Hematol 99, 877–884 (2020). https://doi.org/10.1007/s00277-020-03947-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-03947-1